Contact Congress about H.R. 6166: Lowering Drug Costs for American Families Act

The government could negotiate prices on up to 50 drugs, and those lower prices would apply to private insurance too. Out-of-pocket prescription costs would be capped at $2,000 a year, and insulin copays at $35 a month.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Lowering Drug Costs for American Families Act is a House bill in committee. The latest recorded action: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Latest action on H.R. 6166: Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.

Who this affects: This bill mainly affects people who pay high prescription drug costs, especially those with private insurance who currently don't benefit from Medicare's negotiated prices. It also affects drug companies, insurers, and employers who sponsor health plans.

Why this matters: Prescription drug costs are one of the biggest financial burdens in American healthcare. This bill tries to lower those costs by expanding the government's bargaining power and putting hard caps on what patients pay. But it could also reduce drug company revenues, which critics say might slow down development of new treatments.

Key provisions in H.R. 6166

• Raises the minimum number of drugs the government can negotiate prices on from 20 to 50.
• People with private insurance (group and individual plans) get access to negotiated drug prices by default. Plans must actively opt out for each drug and each period if they don't want to participate.
• Any plan or insurer that opts out of negotiated pricing for a drug must be publicly listed by federal agencies.
• For drugs in the negotiation program, a patient's cost-sharing can't be more than the negotiated price.
• Starting with 2028 negotiations, the government must look at what Australia, Canada, France, Germany, Japan, and the United Kingdom pay for a drug when setting the negotiated price.

How Modern Action helps you take action on H.R. 6166

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about H.R. 6166

What is H.R. 6166?

The government could negotiate prices on up to 50 drugs, and those lower prices would apply to private insurance too. Out-of-pocket prescription costs would be capped at $2,000 a year, and insulin copays at $35 a month.

How do I support or oppose H.R. 6166?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about H.R. 6166?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain H.R. 6166 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.